CO2022014886A2 - 3-fenoxiazetidin-1-il-pirazinas sustituidas que tienen actividad agonista de gpr52 - Google Patents
3-fenoxiazetidin-1-il-pirazinas sustituidas que tienen actividad agonista de gpr52Info
- Publication number
- CO2022014886A2 CO2022014886A2 CONC2022/0014886A CO2022014886A CO2022014886A2 CO 2022014886 A2 CO2022014886 A2 CO 2022014886A2 CO 2022014886 A CO2022014886 A CO 2022014886A CO 2022014886 A2 CO2022014886 A2 CO 2022014886A2
- Authority
- CO
- Colombia
- Prior art keywords
- phenoxyazetidin
- pyrazines
- substituted
- agonist activity
- general formula
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/50—Pyridazines; Hydrogenated pyridazines
- A61K31/501—Pyridazines; Hydrogenated pyridazines not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Neurosurgery (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202063001640P | 2020-03-30 | 2020-03-30 | |
| PCT/EP2021/058099 WO2021198149A1 (en) | 2020-03-30 | 2021-03-29 | Substituted 3-phenoxyazetidin-1-yl-pyrazines having gpr52 agonistic activity |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CO2022014886A2 true CO2022014886A2 (es) | 2022-10-31 |
Family
ID=75362607
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CONC2022/0014886A CO2022014886A2 (es) | 2020-03-30 | 2022-10-19 | 3-fenoxiazetidin-1-il-pirazinas sustituidas que tienen actividad agonista de gpr52 |
Country Status (20)
| Country | Link |
|---|---|
| US (1) | US11780827B2 (https=) |
| EP (1) | EP4126850B1 (https=) |
| JP (1) | JP7617134B2 (https=) |
| KR (1) | KR20220161454A (https=) |
| CN (1) | CN115697997B (https=) |
| AR (1) | AR121675A1 (https=) |
| AU (1) | AU2021250303A1 (https=) |
| BR (1) | BR112022018996A2 (https=) |
| CA (1) | CA3176265A1 (https=) |
| CO (1) | CO2022014886A2 (https=) |
| CR (1) | CR20220554A (https=) |
| DO (1) | DOP2022000203A (https=) |
| EC (1) | ECSP22080683A (https=) |
| IL (1) | IL296823A (https=) |
| JO (1) | JOP20220235A1 (https=) |
| MX (1) | MX2022012067A (https=) |
| PE (1) | PE20221918A1 (https=) |
| PH (1) | PH12022552553A1 (https=) |
| TW (1) | TW202204343A (https=) |
| WO (1) | WO2021198149A1 (https=) |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| TW202206413A (zh) | 2020-04-22 | 2022-02-16 | 美商紐羅克里生物科學有限公司 | Gpr52調節劑及其使用方法 |
| US12115157B2 (en) | 2021-09-14 | 2024-10-15 | Boehringer Ingelheim International Gmbh | 3-phenoxyazetidin-1-yl-heteroaryl pyrrolidine derivatives and the use thereof as medicament |
| CN119143731B (zh) * | 2024-09-13 | 2025-08-26 | 中国海洋大学 | 一种吡嗪酰胺类化合物及其制备方法和应用 |
Family Cites Families (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU2055500A (en) * | 1998-12-23 | 2000-07-31 | Eli Lilly And Company | Aromatic amides |
| WO2009107391A1 (ja) | 2008-02-27 | 2009-09-03 | 武田薬品工業株式会社 | ６員芳香環含有化合物 |
| GB0808668D0 (en) * | 2008-05-13 | 2008-06-18 | Univ Aberdeen | Materials and methods relating to a G-protein coupled receptor |
| JPWO2009157196A1 (ja) | 2008-06-25 | 2011-12-08 | 武田薬品工業株式会社 | アミド化合物 |
| WO2011078360A1 (ja) * | 2009-12-24 | 2011-06-30 | 武田薬品工業株式会社 | アミド化合物 |
| EP2530078A1 (en) * | 2010-01-27 | 2012-12-05 | Takeda Pharmaceutical Company Limited | Thiazole derivative |
| WO2011145735A1 (ja) * | 2010-05-21 | 2011-11-24 | 武田薬品工業株式会社 | チアゾール誘導体 |
| WO2012020738A1 (ja) * | 2010-08-09 | 2012-02-16 | 武田薬品工業株式会社 | 複素環化合物およびその用途 |
| WO2012076063A1 (en) * | 2010-12-10 | 2012-06-14 | Rottapharm S.P.A. | Pyridine amide derivatives as ep4 receptor antagonists |
| KR20180004193A (ko) * | 2015-04-29 | 2018-01-10 | 아레나 파마슈티칼스, 인크. | Gpr52와 관련된 장애의 치료 또는 예방을 위한 gpr52 조절제로서 1-헤테로아릴-인돌린-4-카르복스아미드 |
| AU2016324317A1 (en) * | 2015-09-17 | 2018-03-08 | Coda Biotherapeutics, Inc. | Compositions and methods for treating neurological disorders |
-
2021
- 2021-03-29 BR BR112022018996A patent/BR112022018996A2/pt not_active Application Discontinuation
- 2021-03-29 AR ARP210100766A patent/AR121675A1/es not_active Application Discontinuation
- 2021-03-29 KR KR1020227038002A patent/KR20220161454A/ko not_active Withdrawn
- 2021-03-29 CR CR20220554A patent/CR20220554A/es unknown
- 2021-03-29 AU AU2021250303A patent/AU2021250303A1/en not_active Abandoned
- 2021-03-29 EP EP21716133.0A patent/EP4126850B1/en active Active
- 2021-03-29 JP JP2022559709A patent/JP7617134B2/ja active Active
- 2021-03-29 TW TW110111402A patent/TW202204343A/zh unknown
- 2021-03-29 IL IL296823A patent/IL296823A/en unknown
- 2021-03-29 MX MX2022012067A patent/MX2022012067A/es unknown
- 2021-03-29 CN CN202180025462.7A patent/CN115697997B/zh active Active
- 2021-03-29 WO PCT/EP2021/058099 patent/WO2021198149A1/en not_active Ceased
- 2021-03-29 PE PE2022002146A patent/PE20221918A1/es unknown
- 2021-03-29 PH PH1/2022/552553A patent/PH12022552553A1/en unknown
- 2021-03-29 CA CA3176265A patent/CA3176265A1/en active Pending
- 2021-03-29 US US17/215,759 patent/US11780827B2/en active Active
-
2022
- 2022-09-23 DO DO2022000203A patent/DOP2022000203A/es unknown
- 2022-09-28 JO JOJO/P/2022/0235A patent/JOP20220235A1/ar unknown
- 2022-10-18 EC ECSENADI202280683A patent/ECSP22080683A/es unknown
- 2022-10-19 CO CONC2022/0014886A patent/CO2022014886A2/es unknown
Also Published As
| Publication number | Publication date |
|---|---|
| CA3176265A1 (en) | 2021-10-07 |
| EP4126850B1 (en) | 2024-04-17 |
| CN115697997A (zh) | 2023-02-03 |
| PH12022552553A1 (en) | 2024-01-03 |
| MX2022012067A (es) | 2022-10-13 |
| DOP2022000203A (es) | 2022-11-30 |
| IL296823A (en) | 2022-11-01 |
| US20220356172A1 (en) | 2022-11-10 |
| JP7617134B2 (ja) | 2025-01-17 |
| CR20220554A (es) | 2023-01-09 |
| KR20220161454A (ko) | 2022-12-06 |
| WO2021198149A1 (en) | 2021-10-07 |
| JOP20220235A1 (ar) | 2022-09-28 |
| US11780827B2 (en) | 2023-10-10 |
| EP4126850A1 (en) | 2023-02-08 |
| AU2021250303A1 (en) | 2022-09-22 |
| BR112022018996A2 (pt) | 2022-11-01 |
| ECSP22080683A (es) | 2022-11-30 |
| AR121675A1 (es) | 2022-06-29 |
| CN115697997B (zh) | 2024-07-30 |
| TW202204343A (zh) | 2022-02-01 |
| PE20221918A1 (es) | 2022-12-29 |
| JP2023522307A (ja) | 2023-05-30 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CO2022014886A2 (es) | 3-fenoxiazetidin-1-il-pirazinas sustituidas que tienen actividad agonista de gpr52 | |
| CR20210552A (es) | Inhibidores del inflamasoma nlrp3 | |
| ECSP24014832A (es) | Inhibidores de nlrp3 | |
| ECSP19030002A (es) | 1,2,4-triazolonas 2,4,5-trisustituidas | |
| CL2019002255A1 (es) | 2-heteroaril-3-oxo-2,3-dihidropiridazin-4-carboxamidas. | |
| CO7310531A2 (es) | 4-metil-2,3,8,9,9b-pentaaza-ciclopenta [a] naftalenos | |
| CL2017002650A1 (es) | Compuestos novedosos | |
| CO6300957A2 (es) | Derivados de imidazo -[1,2,b]-piridazina para el tratamiento de enfermedad mediada por cinasa de tirosina c-met | |
| MX2023004920A (es) | Compuestos inhibidores de la proteina 6 del linfoma de linfocitos b (bcl6). | |
| CU20130033A7 (es) | Imidazopiridazinas sustituidas | |
| UY35572A (es) | Nuevos agonistas del receptor de somatostatina subtipo 4 (sstr4) | |
| ECSP17021897A (es) | Compuestos y composiciones como inhibidores de quinasa raf | |
| UY30547A1 (es) | Derivados n-sustituidos de la 6-piridin-4-il quinazolin-2-amina, sus estereoisomeros y sales farmacéuticamente aceptables, proceso de preparacion, composiciones y aplicaciones. | |
| CU20200008A7 (es) | Compuestos de dihidrooxadiazinonas sustituidas útiles en el tratamiento de enfermedades hiperproliferativas, métodos para preparar dichos compuestos y composiciones farmacéuticas que los contienen | |
| CO2017007325A2 (es) | 2,4 diamino-quinolina sustituida como nuevos agentes anti-cancerigenos | |
| CO2022008313A2 (es) | Compuestos químicos | |
| UY32829A (es) | Derivados de 3-heteroaril-metil-imidazo-[1,2-b]-pirididazin - 6 -ilo | |
| CL2018000856A1 (es) | Derivados de éter cíclico de pirazolo[1,5-a]pirimidin-3-carboxiamida. | |
| DOP2024000165A (es) | Compuestos y composiciones para el tratamiento de afecciones asociadas con la actividad del receptor de lpa | |
| AR127031A1 (es) | Derivados de 3-fenoxiazetidin-1-il-heteroaril pirrolidina y el uso de estos como medicamento | |
| UY31805A (es) | Agonistas m1, composiciones farmacéuticas de los mismos, procesos para su preparacion y sus usos para el tratamiento del dolor | |
| UY30699A1 (es) | Derivados sustituidos de 4-fenilamino-quinolina-3-carboxamidas, sales farmacéuticamente aceptables, procesos de preparacion, composiciones conteniéndolos y aplicaciones | |
| UY31812A (es) | Derivados de cinolina como inhibidores de csf-1 | |
| UY32718A (es) | Compuestos derivados de 1, 3, 4-tiadiazol, útiles como agonistas del receptor de esfingosina 1-fosfato | |
| ECSP099644A (es) | Derivados de quinolina, composiciones farmacéuticas que los comprenden y el uso de tales en el tratamiento de enfermedades del sistema nervioso central y periférico |